Health
Auto Added by WPeMatico
Senti Bio raises $105 million for its new programmable biology platform and cancer therapies
Senti Biosciences, a company developing cancer therapies using a new programmable biology platform, said it has raised $105 million in a new round of financing led by the venture arm of life sciences giant Bayer.
The company’s technology uses new computational biological techniques to manufacture cell and gene therapies that can more precisely target specific cells in the body.
Senti Bio’s chief executive, Tim Lu, compares his company’s new tech to the difference between basic programming and object-oriented programming. “Instead of creating a program that just says ‘Hello world’, you can introduce ‘if’ statements and object-oriented programming,” said Lu.
By building genetic material that can target multiple receptors, Senti Bio’s therapies can be more precise in the way they identify genetic material in the body and deliver the kinds of therapies directly to the pathogens. “Instead of the cell expressing a single receptor… now we have two receptors,” he said.
The company is initially applying its gene circuit technology platform to develop therapies that use what are called chimeric antigen receptor natural killer (CAR-NK) cells that can target cancer cells in the body and eliminate them. Many existing cell and gene therapies use chimeric antigen receptor T-cells, which are white blood cells in the body that are critical to immune response and destroy cellular pathogens in the body.
However, T-cell-based therapies can be toxic to patients, stimulating immune responses that can be almost as dangerous as the pathogens themselves. Using CAR-NK cells produces similar results with fewer side effects.
That’s independent of the gene circuit, said Lu. “The gene circuit gets you specificity… Right now when you use a CAR-T cell or a CAR-NK cell… you find a target and hope that it doesn’t affect normal cells. We can build logic in our gene circuits in the cell that means a CAR-NK cell can identify two targets rather than one.”
That increased targeting means lower risks of healthy cells being destroyed alongside mutations or pathogens that are in the body.
For Lu and his co-founders — fellow MIT professor Jim Collins, Boston University professor Wilson Wong and longtime synthetic biology operator Phillip Lee — Senti Bio is the culmination of decades of work in the field.
“I compare it to the early days of semiconductor work,” Lu said of the journey to develop this gene circuit technology. “There were bits and pieces of technology being developed in research labs, but to realize the scale at which you need, this has to be done at the industrial level.”
So licensing work from MIT, Boston University and Stanford, Lu and his co-founders set out to take this work out of the labs to start a company.
“When the company was started it was a bag of tools and the know-how on how to use them,” Lu said. But it wasn’t a fully developed platform.
That’s what the company now has and with the new capital from Leaps by Bayer and its other investors, Senti is ready to start commercializing.
The first products will be therapies for acute myeloid leukemia, hepatocellular carcinoma and other, undisclosed, solid tumor targets, the company said in a statement.
“Leaps by Bayer’s mission is to invest in breakthrough technologies that may transform the lives of millions of patients for the better,” said Juergen Eckhardt, MD, head of Leaps by Bayer. “We believe that synthetic biology will become an important pillar in next-generation cell and gene therapy, and that Senti Bio’s leadership in designing and optimizing biological circuits fits precisely with our ambition to prevent and cure cancer and to regenerate lost tissue function.”
Lu and his co-founders also see their work as a platform for developing other cell therapies for other diseases and applications — and intend to partner with other pharmaceutical companies to bring those products to market.
“Over the past two years, our team has designed, built and tested thousands of sophisticated gene circuits to drive a robust product pipeline, focused initially on allogeneic CAR-NK cell therapies for difficult-to-treat liquid and solid tumor indications,” Lu said in a statement. “I look forward to continued platform and pipeline advancements, including starting IND-enabling studies in 2021.”
The new financing round brings Senti’s total capital raised to just under $160 million and Lu said the new money will be used to ramp up manufacturing and accelerate its work partnering with other pharmaceutical companies.
The current time frame is to get its investigational new drug permits filed by late 2022 and early 2023 and have initial clinical trials begun in 2023.
Developing gene circuits is a new and expanding field with a number of players, including Cell Design Labs, which was acquired by Gilead in 2017 for up to $567 million. Other companies working on similar therapies include CRISPR Therapeutics, Intellius and Editas, Lu said.
Powered by WPeMatico
Sources: Hinge Health has raised $310M Series D at a $3B valuation
Hinge Health, the San Francisco-based company that offers a digital solution to treat chronic musculoskeletal (MSK) conditions — such as back and joint pain — has closed a $310 million in Series D funding, according to sources.
The round is led by Coatue and Tiger Global, and values 2015-founded Hinge at $3 billion post-money, people familiar with the investment tell me. It comes off the back of a 300% increase in revenue in 2020, with investors told to expect revenue to nearly triple again in 2021 based on the company’s booked pipeline.
I also understand that Hinge’s founders — Daniel Perez and Gabriel Mecklenburg — retain voting control of the board. I’ve reached out to CEO Perez for comment and will update this post should I hear back.
Hinge’s existing investors include Bessemer Venture Partners, which backed the company’s $90 million Series C round in February, along with Lead Edge Capital, Insight Partners (which led the Series B), Atomico (which led the Series A), 11.2 Capital, Quadrille Capital and Heuristic Capital.
Originally based in London, Hinge Health primarily sells into U.S. employers and health plans, billing itself as a digital healthcare solution for chronic MSK conditions. The platform combines wearable sensors, an app and health coaching to remotely deliver physical therapy and behavioral health.
The basic premise is that there is plenty of existing research to show how best to treat chronic MSK disorders, but existing healthcare systems aren’t up to the task due to funding pressures and for other systematic reasons. The result is an over tendency to use opioid-based painkillers or surgery, with poor results and often at even greater cost. Hinge wants to reverse this through the use of technology and better data, with a focus on improving treatment adherence.
Meanwhile, Hinge’s jump in valuation is significant. According to sources, the company’s February round produced a valuation of around $420 million, so the new valuation is more than a 6x increase.
Powered by WPeMatico
Color raises $167 million funding at $1.5 billion valuation to expand ‘last mile’ of US health infrastructure
Healthcare startup Color has raised a sizable $167 million in Series D funding round, at a valuation of $1.5 billion post-money, the company announced today. This brings the total raised by Color to $278 million, with its latest large round intended to help it build on a record year of growth in 2020 with even more expansion to help put in place key health infrastructure systems across the U.S. — including those related to the “last mile” delivery of COVID-19 vaccines.
This latest investment into Color was led by General Catalyst, and by funds invested by T. Rowe Price, along with participation from Viking Global investors as well as others. Alongside the funding, the company is also bringing on a number of key senior executives, including Claire Vo (formerly of Optimizely) as chief product officer, Emily Reuter (formerly of Uber, where she played a key role in its IPO process) as VP of Strategy and Operations, and Ashley Chandler (formerly of Stripe) as VP of Marketing.
“I think with the [COVID-19] crisis, it’s really shone the light on that lack of infrastructure. We saw it multiple times, with lab testing, with antigen testing and now with vaccines,” Color CEO and co-founder Othman Laraki told me in an interview. “The model that we’ve been developing, that’s been working really well and we feel like this is the opportunity to really scale it in a very major way. I think literally what’s happening is the building of the public health infrastructure for the country that’s starting off from a technology-first model, as opposed to, what ends up happening in a lot of industries, which is you start off taking your existing logistics and assets, and add technology to them.”
Color’s 2020 was a record year for the company, thanks in part to partnerships like the one it formed with San Francisco to establish testing for healthcare workers and residents. Laraki told me they did about five-fold their prior year’s business, and while the company is already set up to grow on its own sustainably based on the revenue it pulls in from customers, its ambitions and plans for 2021 and beyond made this the right time to help it accelerate further with the addition of more capital.
Laraki described Color’s approach as one that is both cost-efficient for the company, and also significant cost-saving for the healthcare providers it works with. He likens their approach to the shift that happened in retail with the move to online sales — and the contribution of one industry heavyweight in particular.
“At some point, you build Amazon — a technology-first stack that’s optimized around access and scale,” Laraki said. “I think that’s literally what we’re seeing now with healthcare. What’s kind of getting catalyzed right now is we’ve been realizing it applies to the COVID crisis, but also, we started actually working on that for prevention and I think actually it’s going to be applying to a huge surface area in healthcare; basically all the aspects of health that are not acute care where you don’t need to show up in hospital.”
Ultimately, Color’s approach is to rethink healthcare delivery in order to “make it accessible at the edge directly in people’s lives,” with “low transaction costs,” in a way that’s “scalable, [and] doesn’t use a lot of clinical resourcing,” Laraki says. He notes that this is actually very possible once you reasses the problem without relying on a lot of accepted knowledge about the way things are done today, which result in a “heavy stack” versus what you actually need to deliver the desired outcomes.
Laraki doesn’t think the problem is easy to solve — on the contrary, he acknowledges that 2021 is likely to be even more difficult and challenging than 2020 in many ways for the healthcare industry, and we’ve already begun to see evidence of that in the many challenges already faced by vaccine distribution and delivery in its initial rollout. But he’s optimistic about Color’s ability to help address those challenges, and to build out a “last mile” delivery system for crucial care that expands accessibility, while also making sure things are done right.
“When you take a step back, doing COVID testing or COVID vaccinations … those are not complex procedures at all — they’re extremely simple procedures,” he said. “What’s hard is doing them massive scale and with a very low transaction cost to the individual and to the system. And that’s a very different tooling.”
Powered by WPeMatico
Austin-based ReturnSafe raises $3.25 million for its employee health management tools
ReturnSafe, a symptom checking and contact tracing employee health management toolkit for businesses, has raised $3.25 million in financing from investors including Fifty Years and Active Capital.
With companies looking to reopen operations and have their employees return to work safely, management toolkits that track employee health are piling into the market offering all sorts of strategies to maintain a safe work environment.
These include offerings from companies like WorkSafe; or the ProtectWell tool from Microsoft and UnitedHealth; or NSpace, which has similar features and a scheduling tool for booking office space safely.
For its part, ReturnSafe is boasting six-figure monthly recurring revenue and is working with 50 organizations since its launch six months ago.
The pitch to investors and customers is that the need to manage employees and ensure that workspaces are free from health risks is only going to grow in a post-COVID-19 world.
Of course, the best way for employers to ensure the safety and security of their employees is to provide adequate leave and time off if employees are sick, and to ensure that everyone has access to adequate testing at regular intervals should they not be able to work remotely.
Like other companies in the market, ReturnSafe offers a symptoms screener, a testing dashboard, a case management dashboard and a new vaccine management service. In addition to those software tools, ReturnSafe pitches a set of wearable devices with built-in social distancing alarms to ensure that employees maintain safe distances.
Powered by WPeMatico
Mental wellness platform Lyra Health is raising up to $175M at a $2.25B valuation
The coronavirus pandemic has underscored, and often exacerbated, the mental health crisis that exists across the world. Even the spread of remote work is part of the problem: As everyone stays at home, the lack of interaction and watercooler chat has left employees without in-person interaction.
The need for a solution has helped tech-powered mental health solutions raise funding to meet increased demand. In the latest development, it emerged that Lyra Health, a platform that focuses on providing workforces with mental health care, has filed paperwork to raise a $175 million Series E at a $2.25 billion valuation.
The paperwork was uncovered by Prime Unicorn Index. While it is not clear whether the company has closed the round, filings in Delaware usually appear after part or all of the funding has been secured. Prime Unicorn Index notes that the terms surrounding this Series E round include a “pari passu liquidation preference with all other preferred, and conventional convertible, meaning they will not participate with common stock if there are remaining proceeds.” It also noted that Lyra Health’s most recent price per share is $27.47, an up round from the Series D, which priced shares at $14.21.
We are reaching out to the company and investors for a response to the filing. One investor noted that the round has not closed yet.
Past backers of the company include Adams Street Partners, Tenaya Capital, Meritech Capital Partners, IVP and Greylock.
We seem to be in a period of rapid growth rounds getting raised in quick succession for the most promising startups. As with Discord — which confirmed a $100 million round just six months after raising $100 million — Lyra Health also recently raised funding — specifically a $110 million Series D that catapulted it above a $1 billion valuation.
That effectively means the startup doubled its valuation in a handful of months, suggesting rapid growth or key validation. As reported by Forbes, Lyra Health was set to bring in around $100 million in revenue by the end of the year at the time of its prior fundraise.
There have been a number of categories of technology that have seen a bump of usage and interest during this coronavirus pandemic, and sadly — or perhaps usefully, depending on how you look at it — mental health and wellness startups, aimed at helping our well-being in this trying time, have been one of them. Just last week, the meditation app Calm raised $75 million at a $2 billion valuation.
Burlingame, California-based Lyra Health wants to live in offices everywhere. The company helps employers give their employees a suite of safe and confidential tools to support their mental health needs. This is a tricky space to play in, considering that mental health can still feel taboo in workplaces and employees might feel uncomfortable turning to their employers for support. Still, in a world where in-office perks are no longer available, mental health might be a key investment to help startup retention.
Once an employee joins Lyra, the company creates a set of recommendations for the now-patient based on a survey. Lyra Health then can connect patients to its network of thousands of therapists for appointments, consultations and check-ins. The flywheel continues.
During the pandemic, Lyra Health has brought on 80,000 new users, to a total of 1.5 million users last reported.
Tech-enabled mental health care has found tailwinds as the coronavirus pandemic leads to a surge of telehealth, as in-person doctor’s appointments could leave patients at risk. Indeed, Lyra Health started Lyra Blended Care, which pairs video therapy with online lessons and exercises rooted in cognitive behavioral therapy.
Powered by WPeMatico
Cloud-gaming platforms were 2020’s most overhyped trend
It was an unprecedented year for [insert anything under the sun], and while plenty of tech verticals saw shifts that warped business models and shifted user habits, the gaming industry experienced plenty of new ideas in 2020. However, the loudest trends don’t always take hold as predicted.
This year, Google, Microsoft, Facebook and Amazon each leaned hard into new cloud-streaming tech that shifts game processing and computing to cloud-based servers, allowing users to play graphics-intensive content on low-powered systems or play titles without dealing with lengthy downloads.
It was heralded by executives as a tectonic shift for gaming, one that would democratize access to the next generation of titles. But in taking a closer look at the products built around this tech, it’s hard to see a future where any of these subscription services succeed.
Massive year-over-year changes in gaming are rare because even if a historically unique platform launches or is unveiled, it takes time for a critical mass of developers to congregate and adopt something new — and longer for users to coalesce. As a result, even in a year where major console makers launch historically powerful hardware, massive tech giants pump cash into new cloud-streaming tech and gamers log more hours collectively than ever before, it can feel like not much has shifted.
That said, the gaming industry did push boundaries in 2020, though it’s unclear where meaningful ground was gained. The most ambitious drives were toward redesigning marketplaces in the image of video streaming networks, aiming to make a more coordinated move toward driving subscription growth and moving farther away from an industry defined for decades by one-time purchases structured around single-player storylines, one dramatically shaped by internet networking and instantaneous payments infrastructure software.
Today’s products are far from dead ends for what the broader industry does with the technology.
But shifting gamers farther away from one-off purchases wasn’t even the gaming industry’s most fundamental reconsideration of the year, a space reserved for a coordinated move by the world’s richest companies to upend the console wars with an invisible competitor. It’s perhaps unsurprising that the most full-featured plays in this arena are coming from the cloud services triumvirate, with Google, Microsoft and Amazon each making significant strides in recent months.
The driving force for this change is both the maturation of virtual desktop streaming and continued developer movement toward online cross-play between gaming platforms, a trend long resisted by legacy platform owners intent on maintaining siloed network effects that pushed gamers toward buying the same consoles that their friends owned.
The cross-play trend reached a fever pitch in recent years as entities like Epic Games’ Fortnite developed massive user bases that gave developers exceptional influence over the deals they struck with platform owners.
While a trend toward deeper cross-play planted the seeds for new corporate players in the gaming world, it has been the tech companies with the deepest pockets that have pioneered the most concerted plays to side-load a third-party candidate into the console wars.
It’s already clear to plenty of gamers that even in their nascent stages, cloud-gaming platforms aren’t meeting up to their hype and standalone efforts aren’t technologically stunning enough to make up for the apparent lack of selection in the content libraries.
Powered by WPeMatico
Providing healthcare to lower-income communities values Cityblock Health at $1 billion
Cityblock Health, a company that provides healthcare services to low-income communities, is now commanding a high-priced valuation of over $1 billion after venture capitalists poured $160 million into the company.
The round was led by new investor General Catalyst with participation from crossover investor Wellington Management and support from major existing investors, including Kinnevik AB, Maverick Ventures, Thrive Capital, Redpoint Ventures and more, according to a statement from the company.
Cityblock works with community caregivers to work with residents to provide primary care, behavioral health and other services to address social determinants of health, in person and… increasingly… through virtual consultations.
The company first spun out of Alphabet’s Sidewalk Labs in 2017 and initially partnered with EmblemHealth. By relying primarily on licensed clinical social workers, community health partners and a network of specialized practice clinicians and doctors to provide basic primary care and supporting health services, Cityblock believes it can drive down the costs of healthcare.
Some 70,000 patients use Cityblock services in four major U.S. cities, the company said.
To date, Cityblock has raised $300 million.
The company said in a statement that the new funding will be used to support Cityblock’s national expansion in caring for Medicaid and dually-eligible communities, to attract and onboard talent across its product, engineering, data science, clinical and business operations, to launch new service lines and to continue investing in its proprietary technology platform, Commons.
Powered by WPeMatico
With another $2.5 million in funding, Julia Collins’ Planet FWD launches climate-friendly snack brand
Planet FWD, the climate-friendly food startup founded by Zume co-founder Julia Collins, is today launching its first product, Moonshot Snacks. The climate-friendly snack is carbon neutral, organic, kosher, plant-based, non-GMO and has no sugar added.
The crackers come in three flavors: sourdough sea salt, rosemary garlic and tomato basil. A box of crackers costs $5.99.
Planet FWD is also announcing an additional $2.5 million in funding led by Emerson Collective, Concrete Rose, MCJ Collective and Arlan Hamilton, as well as existing investors, including BBG Ventures, January Ventures and Kapor Capital, among others. This is on top of the $2.7 million the startup announced earlier this year.
What’s unique about Planet FWD’s Moonshot Snacks is that it uses ingredients from farmers that use regenerative agriculture practices. Regenerative agriculture is a farming technique that aims to reverse the effects of climate change by capturing carbon in soil and aboveground biomass, which ultimately increases biodiversity, enriches soils and improves watersheds.
“We want to engage customers and show them they have the power to address climate change just with the way they eat,” Collins told TechCrunch. “We can use our food choices as a way to promote better farm management practices and company practices that can help decarbonize the environment.”
Ideally, Planet FWD will be able to show there’s consumer demand for climate-friendly products, Collins said. From there, she hopes that would encourage more farmers to implement these regenerative agriculture practices.
Unlike organic foods, where those specific farms are relatively well-known and identified, that can’t be said for regenerative agriculture. This is where the software element of Planet FWD comes in.
Additionally, Planet FWD is alpha testing a carbon impact assessment. So, if a brand wanted to determine what its current greenhouse gas impact is for its products, the tool could break down where it comes from — whether that’s the packaging, the ingredients, the distribution, etc. From there, the tool would recommend how to reduce the product’s greenhouse gas impact.
“Frankly, I think it’s a privilege to be alive and aware during this time where this is this window of opportunity to address climate change,” Collins said. “We can’t stop it. We can’t reverse it. But we can address it so it’s still possible for people to live on this planet. But the window is closing.”
Moonshot Snacks begins shipping today via its website. On December 16, it will be available via plastic-free grocery store Zero and will have a more traditional retail launch next year.
Planet FWD will create other products down the line, like cookies and chips. But first and foremost, the company’s road map is driven by the supply chain and understanding where there are opportunities to convert farms to regenerative practices.
“Through its sustainable and climate-friendly ingredient platform, Planet FWD is building a movement of more climate-conscious farmers and producers who can lead us toward a better, more sustainable future,” Fern Mandelbaum, managing director at Emerson Collective, said in a statement. “Through Julia’s inclusive leadership and passion, Planet FWD is helping create a new standard for the food industry and its role in being part of climate solutions.”
Powered by WPeMatico
HealNow raises $1.3 million to bring online payments to pharmacies
As the health tech landscape rapidly evolves, another startup is making its presence known. HealNow has closed a $1.3 million round of funding from SoftBank Opportunity Fund and Alabama Futures Fund.
The company was founded by Halston Prox and Joshua Smith. Prox has worked in healthcare for more than a decade with major organizations such as Providence Health, Mount Sinai and Baylor Scott & White, mostly focused on digitizing health records and designing and implementing software for doctors, nurses, etc. Smith, CTO at the company, has been a developer since 2012.
The duo founded HealNow to become the central nervous system for order and delivery of prescriptions, according to Prox. Your average payments processing system isn’t necessarily applicable to pharmacies large and small because of the complexities of health insurance and the regulatory landscape.
Not only is it costly to facilitate online payments for pharmacies, but they also have their own pharmacy management systems and workflows that can be easily disrupted by moving to a new payments system.
HealNow has built a system that’s specifically tailored to pharmacies of any shape or size, from grocery stores to mom and pop pharmacies and everything in between. It’s a white label solution, meaning that any pharmacy can put their brand language on the product.
“We’re embedded in their current workflows and pharmacies don’t have to do anything manual, even if they’re using a pharmacy management system,” said Prox.
When a user looks to get a prescription from their pharmacy, they are sent a link that allows them to securely answer any questions that may be necessary for the pickup, enter insurance info, make a payment and schedule a curbside pickup or a delivery. The tech also integrates with third-party delivery services for pharmacies that offer deliveries.
This technology has been particularly important during the COVID-19 pandemic, giving smaller pharmacies the chance to compete with bigger chains who have digital solutions already set up that allow for curbside pick up. This is especially true now that Amazon has gotten into the space with the launch of Amazon Pharmacy.
HealNow is a SaaS company, charging a monthly subscription fee for use of the platform, as well as a service fee for prescriptions purchased on the platform. However, that service fee is a flat rate that never changes based on the cost of the prescription.
The space is crowded and growing more crowded, with competitors like NimbleRX and Capsule offering their own spin on simplifying and digitizing the pharmacy. One big difference for HealNow, says Prox, is that the startup has no intention of ever being a pharmacy, but rather serving pharmacies in a way that doesn’t disrupt their current workflow or system.
“We’re not a pharmacy, and we want to enable all these pharmacies to be online,” said Prox. “To do that we have to do that in an unbiased way by focusing on being a complete tech company.”
The funding is going primarily toward building out the sales and marketing arms of the company to continue fueling growth. HealNow has a foothold in the West, Southwest and Middle America, and is opening an office in Birmingham to sprint across the East Coast. Prox says the company is processing thousands of orders a day and tens of thousands of orders each month.
HealNow launched in 2018 after graduating from the Entrepreneurs Roundtable Accelerator .
Powered by WPeMatico
Atlanta-based Sanguina wants to make fingernail selfies a digital biomarker for iron deficiency
Sanguina, an Atlanta-based health technology developer, is launching a mobile app in the Google Play Store that uses pictures of fingernails to determine whether or not someone is getting enough iron.
The app measures hemoglobin levels, which are a key indicator of anemia, by analyzing the color of a person’s fingernail beds in a picture.
These fingernail selfies could be used to determine anemia for the more than 2 billion people who are affected by the condition — including women, children, athletes and the elderly.
Iron deficiencies can cause fatigue, pregnancy complications and, in severe cases, even cardiac arrest, the company said. AnemoCheck is the first smartphone application to measure hemoglobin levels, the company said — and through its app people can not only determine whether or not they’re anemic but also use the app’s information to address the condition, the company said.
Sanguina’s technology uses an algorithm to determine the amount of hemoglobin in the blood based on an examination and analysis of the coloration of the nail bed.
Created by Dr. Wilbur Lam, Erika Tyburski and Rob Mannino, the company was born out of research conducted at the Georgia Institute of Technology and Emory University.
“This non-invasive anemia detection tool is the only type of app-based system that has the potential to replace a common blood test,” said Dr. Lam, a clinical hematologist-bioengineer at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta, associate professor of pediatrics at Emory University School of Medicine and a faculty member in the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Tech.
So far, Sanguina has raised more than $4.2 million in funding from The Seed Lab, XRC Labs and grants from The National Science Foundation and The National Institutes of Health, according to a statement.
Powered by WPeMatico